

2nd World Congress on

Health Economics Policy & Outcomes Research

June 29-30, 2017 | Madrid, Spain

A MULTICENTRIC EVALUATION OF CONSUMABLES AND TRANSPORTS COST OF BREAST CANCER PATIENT'S TREATED BY TRASTUZUMAB ACCORDING TO THE ADMINISTRATION FORM (IV VERSUS SC)

N.Bahmad^a, R.Alfonsi^b, C.Blein^c, C.Bernard Marty^d, A.Jaffre^e, G.Lebozec^f, A.Malik^g, M.A Mouret-Reynier^h, N.Perezⁱ, V.Priou^j, M.Prodel^k, Jf Tournamille^k^a ROCHE, France^b Polyclinique Gentilly, France^c HEVA, France^d Clinique Pasteur, France^e CLCC Bergonie, France^f CH Lorient, France^g CLCC Antoine Lacassagne, France^h CLCC Jean Perrin, Franceⁱ Institut Franco- Britannique, France^j CHU d'Orleans , France^k CHU de Tours, France

Different published clinical studies have demonstrated the non-inferiority of trastuzumab subcutaneous (SC) administration versus intravenous (IV) in terms of efficacy, safety and preference in the treatment of patients with HER2 positive [1-2]. Health facilities wanted to have a multicenter evaluation, using data collected in real life, of the economic impact generated between the two administrations forms.

A sampling plan from 9 health facilities have been conducted to collect economic consumables data for breast cancer patients care pathway's (all stages) under trastuzumab (IV versus SC). The economic perspective retained was health facilities.

Multicentric evaluation collected 417 questionnaires describing the care pathway of 411 patients, including 245 patients treated within a SC administration form (60%) versus 167 patients within an IV form (40%).

The average cost of consumables for preparation and administration, expressed in euro 2016, is €1.35 VAT (\pm €0.47) with the SC routes and €12.42 VAT (\pm €2.20) with the IV routes. Per patient SC administration resulted in significantly cost saving of €11.07 VAT (\pm €1.36).

The average transport cost for a patient treated within a SC administration form is €17.57 VAT (\pm €13.97) and €22.22 VAT (\pm €13.93) within an IV form. This cost is significantly lower by €4.65 VAT (\pm €13.95) for the SC form. This result is induced by the correlation existing between the patient mode of transport (light health vehicle or personal transport) and the administration form. A more important mode of hospital exit per light health vehicle for the IV form is significantly observed.

Biography

Nadia Bahmad is Presently working in ANMS National Drug Safety Agency and Health Products as Unit Manager access to innovation and development . In 2014 she worked as a Project Manager within the Service Medicines Evaluation.

cblein@hevaweb.com

Notes: